Physician profile
Mark M Malicki
NPI 1083619209
$7,616.38
in general payments reported to CMS, 2019-2025
43 companies · $1,457 in 2025
The $1,457 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $619 · 2021: $1,004 · 2022: $1,260 · 2023: $1,126 · 2024: $1,363 · 2025: $1,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,926 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,925.77 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,378.12 | 2019-2025 | |
| Abbvie INC. | $875.72 | 2019-2025 | |
| Glaxosmithkline, LLC. | $686.49 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $569.76 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $359.60 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $349.45 | 2019-2025 | Airsupra, Farxiga |
| Tactile Systems Technology INC | $318.58 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Amarin Pharma, INC. | $296.59 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $236.49 | 2019-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $230.65 | 2022-2025 | Eliquis |
| Merck Sharp & Dohme LLC | $215.59 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Otsuka America Pharmaceutical, INC. | $211.07 | 2020-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $195.81 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $194.17 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.75 | 2019-2025 | Jardiance |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $136.88 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $115.29 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $113.42 | 2020-2024 | Veozah |
| Biohaven Pharmaceuticals, INC. | $110.42 | 2021 | |
| Janssen Pharmaceuticals, INC | $105.47 | 2019-2022 | |
| Dexcom, INC. | $75.99 | 2021-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $71.71 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $63.83 | 2020 | |
| Sanofi Pasteur INC. | $50.62 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $49.08 | 2023-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $48.50 | 2019-2024 | |
| Boston Scientific Corporation | $46.39 | 2022-2025 | Watchman Flx |
| Seqirus USA INC | $46.13 | 2022-2025 | Fluad, Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $36.16 | 2019-2021 | |
| Stryker Corporation | $27.24 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Genentech USA, INC. | $24.22 | 2020 | |
| Medtronic, INC. | $21.51 | 2025 | Intellis Adaptivestim |
| Esperion Therapeutics, INC. | $21.25 | 2021 | |
| Alexion Pharmaceuticals, INC. | $20.69 | 2023 | Ultomiris |
| Opko Pharmaceuticals, LLC | $19.46 | 2023 | Rayaldee |
| Kowa Pharmaceuticals America, INC. | $19.44 | 2025 | Zoryve |
| Verona Pharma, INC. | $17.98 | 2025 | Ohtuvayre |
| Eisai INC. | $16.41 | 2020 | |
| Collegium Pharmaceutical, INC. | $15.37 | 2023 | Belbuca |
| Teva Pharmaceuticals USA, INC. | $13.35 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.30 | 2024 | Voquezna |
| Shire North American Group INC | $11.95 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Malicki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.